Company intelligence / Profile preview

Amuna Pharmaceuticals

Great Falls, Virginia, United States

Ownership: Private
Development stage: Other

Overview

Amuna Pharmaceuticals is developing liver-targeted mitochondrial uncouplers. Their lead candidate, AM-101, has shown promising preclinical results in reducing body weight and improving insulin sensitivity in animal models by increasing metabolic rate without the systemic toxicity traditionally associated with non-selective mitochondrial uncouplers.

Therapeutic areas: EndocrinologyGastroenterology
Modalities: Small molecule
Industry: Biotech

Partnerships

Allied-Bristol Life Sciences

Beyond the preview

Go deeper on Amuna Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Amuna Pharmaceuticals.

Explore the full profile